Registry for long-term treatment outcomes of psoriasis and psoriatic arthritis in Germany
Long-Term Benefits and Safety of Systemic Psoriasis Therapy: German Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics
This study is tracking the long-term results of different treatments for people with moderate to severe psoriasis and psoriatic arthritis in Germany to see how well they work and what side effects they may have.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universitätsklinikum Hamburg-Eppendorf Academic / other |
| Drugs / interventions | adalimumab, methotrexate, efalizumab, infliximab, ustekinumab |
| Locations | 1 site (Hamburg) |
| Trial ID | NCT01848028 on ClinicalTrials.gov |
What this trial studies
The PsoBest registry collects data on the long-term treatment outcomes of patients with moderate to severe psoriasis and psoriatic arthritis in Germany. It documents the effectiveness, safety, and patient-reported outcomes of systemic therapies, including both conventional and biologic treatments. The registry aims to evaluate the long-term course of treatment for approximately 3,500 patients, focusing on real-world effectiveness and optimal maintenance dosages. By analyzing this data, the registry seeks to provide insights into treatment benefits, side effects, and predictors of response over time.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of plaque-type psoriasis or psoriatic arthritis who are starting a specific systemic drug for the first time.
Not a fit: Patients who are currently participating in other clinical trials or who do not provide informed consent will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could improve treatment strategies and outcomes for patients with psoriasis and psoriatic arthritis.
How similar studies have performed: Other similar registries have shown success in documenting treatment outcomes and improving patient care, indicating that this approach is both valuable and tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a dermatologist * age ≥ 18 years * being administered a specific systemic drug for the first time * informed consent to participate * sufficient language skills (German) Exclusion criteria: * lack of informed consent * patients being participants of clinical trials at the day of admission to the registry (if a patient is included into a clinical trial during the registry follow-ups, the patient data will be recorded, but analysed separately)
Where this trial is running
Hamburg
- Nationwide group of dermatological centers, hospitals and medical offices — Hamburg, Germany (Recruiting)
Study contacts
- Principal investigator: Matthias Augustin, Prof. Dr. — Universitätsklinikum Hamburg-Eppendorf
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.